INTRODUCTION
============

Glycogen synthase kinase-3 (Gsk-3) enzymes Gsk-3α and Gsk-3β are intracellular kinases that together regulate the activity of numerous signal transduction pathways ([@B21]). The genetic deletion of *Gsk-3α* and *Gsk-3β* (referred to hereafter as *Gsk-3* double knockout \[*Gsk-3* DKO\]; [@B10]) in mouse embryonic stem cells (ESCs) revealed the importance of Gsk-3 activity in the regulation of pluripotency; *Gsk-3* DKO ESCs are unable to undergo differentiation, even in the absence of leukemia inhibitory factor ([@B10]). A recently identified novel role for Gsk-3 activity is the regulation of DNA methylation via N-myc and the de novo DNA methyltransferase 3a, isoform 2 (Dnmt3a2), in mouse ESCs ([@B38]). Although initially identified in *Gsk-3* DKO ESCs, further experimentation showed that treating wild-type ESCs with a small-molecule inhibitor of Gsk-3 activity also reduced DNA methylation, as did constitutive activation of phosphatidylinositol 3-kinase (PI3K), which also inhibits Gsk-3 activity ([@B38]). It remains an open question as to whether reduced DNA methylation contributes to the regulation of pluripotency in mouse ESCs.

Imprinted loci are distinct from other alleles due to their retention of DNA methylation, which is inherited from either the mother (maternal) or father (paternal; [@B24]). De novo methyltransferase activity has been shown to be required for the establishment and maintenance of DNA methylation at imprinted loci ([@B7]; [@B18]), and, as predicted, DNA methylation in *Gsk-3* DKO ESCs was reduced at two imprinted loci, *H19/Igf2* and *Igf2r/Air* (Igf2 = insulin-like growth factor 2; [@B38]). There are ∼150 imprinted genes identified in mice ([@B51]), and we sought to determine whether the reduced DNA methylation in *Gsk-3* DKO ESCs extended to other imprinted loci. The development of DNA methylation capture based on affinity to the methyl-binding domain of human methyl-CpG binding domain 2 (MBD2; [@B5]), combined with next-generation DNA sequencing technology (MBD-Seq; [@B30]), allowed us to ask which regions of the genome display DNA hypomethylation in *Gsk-3* DKO ESCs.

Here we present the genome-wide analysis of regions with reduced DNA methylation in *Gsk-3* DKO ESCs. Consistent with our earlier study, we find DNA hypomethylation at a majority of the known imprinted genes in the mouse genome. Moreover, the Methyl­Miner--Sequencing by Oligonucleotide Ligation and Detection (SOLiD) workflow allowed us to demonstrate that reduced DNA methylation in *Gsk-3* DKO ESCs occurred precisely at differentially methylated regions (DMRs), which were previously shown to contain the experimentally defined imprinting control regions (ICRs) for multiple imprinted genes ([@B12]; [@B52]; [@B8]). We provide extensive experimental validation of bioinformatically identified DMRs by performing bisulfite sequencing. In addition, we quantitatively measure gene expression for 91 imprinted genes in *Gsk-3* DKO ESCs and correlate the changes in gene expression with changes in DNA methylation. Furthermore, we find that many Gsk-3--dependent DMRs map precisely to DMRs identified in uniparental ESCs ([@B17]). In addition, we show that many nonimprinted genes, such as the pluripotency-related transcription factor *Klf4* ([@B47]) and the entire *Hoxa* locus ([@B42]), have reduced DNA methylation in *Gsk-3* DKO ESCs. Finally, we compare the DMRs obtained from this study with genes identified as having parent-of-origin bias in the mouse brain ([@B14]) and find an extensive correlation between the data sets. The data presented here offer a global view of the effects on DNA methylation in Gsk-3 DKO ESCs and provide a framework for an integrative analysis of gene expression and DNA methylation status that should be useful for better understanding the effect of signal transduction pathways on epigenetic modifications.

RESULTS
=======

MBD-Seq in wild-type and Gsk-3 DKO ESCs
---------------------------------------

We previously observed decreased DNA methylation at the ICRs for *H19/Igf2* and *Igf2r/Air* in *Gsk-3* DKO ESCs due to reduced expression of the de novo DNA methyltransferase *Dnmt3a2* ([@B38]). On the basis of these findings, we reasoned that decreased *Dnmt3a2* expression might also be affecting the maintenance of DNA methylation at other imprinted loci in a Gsk-3xdependent manner. To investigate this possibility, we chose an unbiased approach to locating all of the regions of the mouse genome that have reduced DNA methylation in ESCs. MethylMiner uses a biotinylated recombinant fragment of the human MBD2 protein to enrich for fragments of methylated DNA. Therefore MethylMiner was used to obtain methylated genomic DNA from wild type (WT) and *Gsk-3* DKO ESCs. After shearing high--molecular weight genomic DNA into 200-- to 250--base pair fragments, we captured methylated DNA on biotinylated recombinant human MBD2 bound to streptavidin-coated Dynabeads. After washing away unmethylated DNA, consecutive elutions were performed under low-salt (600 mM NaCl) and high-salt (2 M NaCl) conditions to liberate DNA from the MBD2 protein. The 2 M fraction is expected to contain the DNA fragments that are most highly methylated, since the lower salt will elute DNA that is less tightly bound to the beads, that is, less methylated. Using 15 μg of input genomic DNA, we recovered ∼9% of the DNA in the 600 mM and 2 M fractions combined (Supplemental Figure S1).

The eluted DNA was then used to prepare a library for next-generation sequencing using a SOLiD instrument. We prepared one library each of the WT and *Gsk-3* DKO 600 mM fraction and two libraries from each of the WT and *Gsk-3* DKO 2M fraction. In addition, we also created libraries from unenriched input DNA from each cell line. SOLiD sequencing yielded \>630,000,000 reads, averaging almost 80,000,000 reads per library. After removing clonal reads, the number of unique starts ranged from 2 × 10^7^ to 2.5 × 10^7^ in the 600 mM fraction and from 6 × 10^6^ to 8 × 10^6^ in the 2 M fraction (Supplemental Table S1). This yielded ∼4--5% coverage of the genome having \>1x unique starts (Supplemental Figure S2).

Peak detection by Model-based Analysis for ChIP-Seq (MACS) was used to identify genomic regions where DNA methylation was significantly reduced in the *Gsk-3* DKO ESCs compared with WT ESCs. Focusing on the 2 M fraction, we identified 29,029 DMRs, which had a mean size of 439 base pairs and together comprised 12.7 Mb, or 0.50% of the mouse genome (Supplemental Table S2). The mean score for these peaks was 128, and the SD was 121. The DMRs were further subdivided into those that were 1 SD or higher than the mean (1SD; i.e., scoring \>249) and 2 SDs or higher than the mean (2SD; i.e., scoring \>370). Using these metrics, we obtained a total of 2545 peaks (8.8% of all peaks identified) that were 1SD (total size 1.6 Mb). Of these, 993 peaks were 2SD (total size 683 kb; Supplemental Table S2). As expected, the same analysis of DMRs identified from the 600 mM fraction yielded an even larger number of DMRs: 3929 peaks that were 1SD, and, of these, 1540 peaks that were 2SD (Supplemental Table S2). Given the smaller number of peaks and the greater enrichment for the greatest amount of DNA methylation, we focused on the 1SD and 2SD peaks from the 2 M faction for the remainder of our analyses.

Examination of imprinted loci for Gsk-3-dependent DMRs
------------------------------------------------------

We next set out to analyze bioinformatically the MethylMiner-SOLiD data. Because we previously demonstrated a role for Gsk-3 in the maintenance of DNA methylation at the imprinted loci *H19/Igf2* and *Igf2r/Air* ([@B38]), we first asked whether DNA methylation was reduced at additional imprinted loci. ICRs are known to function both locally and at a distance ([@B26]; [@B11]), and therefore we determined whether there were any *Gsk-3*--dependent DMRs within 250 kb of a known imprinted gene. Of the 102 imprinted genes we examined, we found that 77% (78 of 102) had *Gsk-3*--dependent DMRs nearby (Supplemental Table S3). Both maternally imprinted and paternally imprinted loci were essentially equally affected (36 paternally imprinted genes and 42 maternally imprinted genes), which suggested that Gsk-3 activity maintains DNA methylation at imprinted loci regardless of the parent-of-origin imprints.

We were particularly satisfied to find that this unbiased approach to analyzing DNA methylation revealed hypomethylation in *Gsk-3* DKO ESCs at the *H19/Igf2* and *Igf2r/Air* DMRs that we had analyzed previously ([@B38]). In fact, we saw remarkable concordance between the location of experimentally defined ICRs and *Gsk-3*-dependent DMRs, including the *Kcnq1/Kcnq1ot1* ([@B12]), *Gnas/Nespas* ([@B8]), and *Rasgrf1* ([@B37]) loci. Raw data showing the mapping of individual sequencing reads from WT and *Gsk-3* DKO ESCs at the *Gnas/Nespas* locus, along with those regions called peaks, are shown in [Figure 1A](#F1){ref-type="fig"}.

![MBD-Seq in WT and Gsk-3 DKO mouse embryonic stem cells. (A) Bam files visualized in Integrative Genome Viewer (IGV) showing aligned sequence reads from WT and *Gsk-3α^−/−^;Gsk-3β^−/−^* (DKO) ESCs at the *Gnas*/*Nespas* locus, whose exon/intron structure is also shown. Vertical red bars represent differentially methylated peaks as determined by MACS. (B) Cartoon schematic of the *Gnas*/*Nespas* locus, showing the DMR locations as identified by MACS (in red), along with the region validated by bisulfite sequencing (in blue). Bisulfite sequencing results for this region in WT and Gsk-3 DKO ESCs are represented by lollipop diagrams. Each circle represents a CpG dinucleotide; horizontal rows represent individual clones, and vertical columns show the position of each CpG. Filled-in circles represent methylated cytosines, and open circles represent unmethylated cytosines. (C) qPCR data showing relative quantification of *Gnas* and *Nespas* gene expression in WT and Gsk-3 DKO ESCs compared with glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Each experiment shown was performed in triplicate.](2139fig1){#F1}

Independent validation of MBD-Seq data via bisulfite sequencing
---------------------------------------------------------------

Given that *Gsk-3*-dependent DMRs were identified computationally at the end of our MethylMiner-SOLiD workflow, it was critical to use an independent method to confirm the validity of these DMRs. To do this, we used conventional bisulfite conversion of genomic DNA, followed by PCR, cloning, and Sanger sequencing ([@B13]). We selected 20 DMRs for validation, corresponding to 14 distinct genomic loci, which were obtained via MethylMiner-Seq. We included the *H19* DMR, previously shown to be *Gsk-3* dependent ([@B38]), as a positive control. Of the remaining 19 DMRs, 15 were from the 2 M fraction and four were from the 600 mM fraction ([Table 1](#T1){ref-type="table"}). Several known imprinted genes---*Blcap/Nnat*, *Gnas*, *Mest/Copg2*, *Peg3*, *Kcnq1ot1*, and *Begain*---were analyzed. We also examined additional genes of interest that contained *Gsk-3*-dependent DMRs---*Pax3*, *En1*, *Adar*, *Klf4*, *Cdc42*, *Fkbp6*, and *Mycn*. Our goal was to obtain at least 12 nonidentical clones from both WT and *Gsk-3* DKO ESCs for each DMR. Representative data showing the locations of *Gsk-3*-dependent DMRs at the *Gnas/Nespas* ([@B8]), *Mest/Copg2* ([@B25]), *Blcap/Nnat*, *Kcnq1ot1* ([@B12]), and *Klf4* ([@B47]) loci, as well as the regions that were validated by bisulfite sequencing, are shown in [Figures 1B](#F1){ref-type="fig"} and [2, A--D](#F2){ref-type="fig"}. For all of the *Gsk-3*-dependent DMRs tested, we found statistically significant differences in DNA methylation between WT and *Gsk-3* DKO ESCs ([Table 1](#T1){ref-type="table"}, *p* \> 0.05, two-tailed Student\'s *t* test). Further increasing our confidence that DMRs identified in *Gsk-3* DKO ESCs accurately denoted genomic regions involved in imprinting, two *Gsk-3*-dependent DMRs were found ∼30 kb upstream of the *Rasgrf1* gene ([Figure 3](#F3){ref-type="fig"}), a region previously identified experimentally to contain a differentially methylated ICR ([@B37]). (The *Rasgrf1* DMR was unable to be validated by bisulfite sequencing due to the presence of repetitive elements that prevented successful PCR.)

![Reduced DNA methylation at imprinted loci in Gsk-3 DKO mouse ESCs. (A) Schematic of the *Mest*/*Copg2* locus, showing the DMR locations as identified by MACS (in red), along with the region validated by bisulfite sequencing (in blue). Bisulfite sequencing results for this region in WT and Gsk-3 DKO ESCs are represented by lollipop showing relative quantification of *Mest* and *Copg2* gene expression in WT and Gsk-3 DKO ESCs compared with GAPDH. Each experiment shown was performed in triplicate. (B) Schematic of the *Blcap*/*Nnat* locus, showing the DMR locations as identified by MACS (in red), along with the region validated by bisulfite sequencing (in blue). Bisulfite sequencing results for this region in WT and Gsk-3 DKO ESCs are represented by lollipop diagrams as described for [Figure 1](#F1){ref-type="fig"}. qPCR data showing relative quantification of *Blcap* and *Nnat* gene expression in WT and Gsk-3 DKO ESCs compared with GAPDH. Each experiment shown was performed in triplicate. (C) Schematic of the *Kcnq1* locus, showing the DMR locations as identified by MACS (in red), along with the region validated by bisulfite sequencing (in blue). Bisulfite sequencing results for this region in WT and Gsk-3 DKO ESCs are represented by lollipop diagrams as described for [Figure 1](#F1){ref-type="fig"}. qPCR data showing relative quantification of *Kcnq1* gene expression in WT and Gsk-3 DKO ESCs compared with GAPDH. Each experiment shown was performed in triplicate. (D) Schematic of the *Klf4* locus, showing the DMR locations as identified by MACS (in red), along with the region validated by bisulfite sequencing (in blue). Bisulfite sequencing results for this region in WT and Gsk-3 DKO ESCs are represented by lollipop diagrams as described for [Figure 1](#F1){ref-type="fig"}. qPCR data showing relative quantification of *Klf4* gene expression in WT and Gsk-3 DKO ESCs compared with GAPDH. Each experiment shown was performed in triplicate.](2139fig2){#F2}

![*Rasgrf1* DMR identified in Gsk-3 DKO ESCs. Schematic representation of the murine *Rasgrf1* genomic locus (chr9:89,767,822-89,818,418) and location of Gsk-3--dependent DMRs located ∼30 kb upstream of the gene in the vicinity of the ICR for *Rasgrf1*.](2139fig3){#F3}

###### 

Summary of *Gsk-3*--dependent DMR validation by bisulfite sequencing.

  Locus            DMR genomic coordinates     WT% CpG   DKO% CpG   Fraction
  ---------------- --------------------------- --------- ---------- ----------
  *Pax3*           chr1:78191696-78192257      51.8      15         2 M
  *En1*            chr1:122496266-122497436    45.3      18.7       2 M
  *Blcap*/*Nnat*   chr2:157385054-157386455    77.4      8.1        2 M
  *Gnas*           chr2:174120416-174122205    63.6      5.8        2 M
  *Gnas*           chr2:174122344-174123811    43.2      18.7       2 M
  *Gnas*           chr2:174123824-174124999    36.8      8.7        2 M
  *Gnas*           chr2:174125041-174126654    67.3      17.5       2 M
  *Adar*           chr3:89471020-89471670      80.4      15.6       2 M
  *Klf4*           chr4:55540960-55541232      86.3      13.0       2 M
  *Cdc42*          chr4:136927927-136928474    69.0      35.6       2 M
  *Fkbp6*          chr5:135725089-135726550    88.8      48.7       600 mM
  *Mest*/*Copg2*   chr6:30682552-30683326      80.7      13.0       2 M
  *Mest*/*Copg2*   chr6:30685155-30685990      86.3      19.1       2 M
  *Peg3*           chr7:6680997-6682243        44.4      1.1        600 mM
  *H19*            chr7:149825745-149826024    47.2      24.4       600 mM
  *Kcnq1*          chr7:150480888-150482586    90.7      35.1       2 M
  *Kcnq1*          chr7:150491439-150492052    97.1      87.2       600 mM
  *Kcnq1*          chr7:150526408-150527088    89.0      75.3       600 mM
  *Mycn*           chr12:12943555-12944660     54.2      13.0       2 M
  *Begain*         chr12:110311312-110311914   81.2      24.3       2 M

Genomic loci and chromosomal coordinates of each DMR. Also shown is the percentage of DNA methylation at each validated DMR in WT and *Gsk-3* DKO ESCs and the fraction in which the DMR was identified (2 M or 600 mM). All *p* \< 0.05.

Functional enrichment analysis of Gsk-3--dependent DMRs
-------------------------------------------------------

Because the 2 M DMRs had a greater level of statistical significance, we focused on the 2503 DMRs identified in this fraction to determine whether there were underlying functional relationships among the genes that were located near *Gsk-3*-dependent DMRs. We used ToppFun, within the ToppGene Suite, to perform this functional enrichment ([Table 2](#T2){ref-type="table"} and Supplemental Table S4; [@B6]). The most common Gene Ontology (GO) Molecular Function was nucleic acid binding transcription factor activity (*p* = 8.99 × 10^−22^; [Table 2](#T2){ref-type="table"}). Of the 1011 terms (genes) associated with this function in the genome, 251 were represented in the 2 M DMR fraction. In fact, the top 9 GO terms all describe DNA-binding activity (only top 5 shown). More specifically, transcription factors containing a homeodomain were found to be highly enriched among the genes associated with *Gsk-3*--dependent DMRs (91 of 314 terms, *p* = 7.7 × 10^−12^), with the *Fox* (F-box) and *Pax* (Paired homeobox) gene families highly represented (14 of 43, *p* = 7.86 × 10^−6^, and 5 of 9, *p* = 7.11 × 10^−3^, respectively). The greatest enrichments for mouse phenotypes associated with the 2 M DMRs were abnormal nervous system development and abnormal heart morphology (195 of 779 terms, *p* = 6.6 × 10^−6^; 186 of 771 terms, *p* = 3.75 × 10^−4^, respectively; [Table 2](#T2){ref-type="table"}). Not surprisingly, given these two predicted categories of phenotypes, the most enriched biological process was embryo development (216 of 830 terms, *p* = 4.18 × 10^−26^). Of interest, enrichment analysis also revealed that *Gsk-3*--dependent DMRs were highly represented among the genes whose expression is affected by the pesticide vinclozolin, whose effects have been associated with transgenerational epigenetic effects in male rats (250 of 1263, *p* = 2.15 × 10^−10^; [@B2]). Similar gene enrichment results were found among the *Gsk-3*--dependent DMRs in the 600 mM fraction (Supplemental Table S4).

###### 

Summary of ToppFun functional enrichment analysis/2M fraction.

  Category                                                            ID           *p* value
  ------------------------------------------------------------------- ------------ ----------------
  GO: Molecular function                                                           
  Nucleic acid--binding transcription factor activity                 GO:0001071   8.99 × 10^−22^
  Sequence-specific DNA-binding transcription factor activity         GO:0003700   1.59 × 10^−21^
  Sequence-specific DNA binding                                       GO:0043565   1.05 × 10^−17^
  Regulatory-region DNA binding                                       GO:0000975   3.89 × 10^−11^
  Regulatory-region nucleic acid binding                              GO:0001067   3.89 × 10^−11^
  GO: Biological process                                                           
  Embryo development                                                  GO:0009790   6.93 × 10^−19^
  Regulation of developmental process                                 GO:0050793   3.64 × 10^−18^
  Organ morphogenesis                                                 GO:0009887   5.52 × 10^−17^
  Regulation of multicellular organismal development                  GO:2000026   8.69 × 10^−17^
  GO: Cellular component                                                           
  Cell junction                                                       GO:0030054   2.46 × 10^−10^
  Cell projection                                                     GO:0042995   1.43 × 10^−9^
  Cell--cell junction                                                 GO:0005911   1.89 × 10^−8^
  Neuron projection                                                   GO:0043005   6.43 × 10^−8^
  Mouse phenotype                                                                  
  Abnormal nervous system development                                 MP:0003861   4.18 × 10^−5^
  Perinatal lethality                                                 MP:0002081   1.35 × 10^−4^
  Domain                                                                           
  Homeodomain-like                                                    IPR009057    7.70 × 10^−12^
  Homeodomain-rel                                                     IPR012287    2.00 × 10^−10^
  Homeobox                                                            IPR001356    8.68 × 10^−10^
  Interaction                                                                      
  SMAD3 interactions                                                  int:SMAD3    3.08 × 10^−5^
  SMAD2 interactions                                                  int:SMAD2    5.08 × 10^−5^
  MAPK1 interactions                                                  int:MAPK1    7.13 × 10^−5^
  CTNNB1 interactions                                                 int:CTNNB1   3.20 × 10^−4^
  Transcription factor--binding site                                               
  RTAAACA_V\$FREAC2_01                                                             3.06 × 10^−6^
  RTTTNNNYTGGM_UNKNOWN                                                             1.60 × 10^−5^
  TGGAAA_V\$NFAT_Q4_01                                                             3.82 × 10^−5^
  Gene family                                                                      
  CD molecules                                                        CD           2.48 × 10^−6^
  Forkhead box genes                                                  FOX          7.86 × 10^−6^
  Drug                                                                             
  Vinclozolin                                                         C025643      2.15 × 10^−10^
  2-(1′H-Indolo-3′-carbonyl)thiazole-4-carboxylic acid methyl ester   C548651      2.40 × 10^−10^
  Mustard gas                                                         D009151      4.46 × 10^−10^
  Calcitriol                                                          D002117      1.86 × 10^−9^

Enrichment analysis of 2245 of 2503 genes located near a *Gsk-3*--dependent DMR from the 2 M fraction.

Comparison of Gsk-3-dependent DMRs with brain imprinted genes
-------------------------------------------------------------

[@B14] used RNA-Seq to identify ∼1300 mRNA transcripts in the mouse brain that exhibit a parent-of-origin bias, suggesting that these represent potential new imprinted genes. This study did not, however, examine DNA methylation, the primary epigenetic mark associated with genomic imprinting. Nonetheless, we performed a meta-analysis of their data and ours to determine whether there were *Gsk-3*--dependent changes in DNA methylation that accompanied the parent-of-origin changes in gene expression at these putative imprinted loci. As we had done previously, we determined which brain imprinted genes had *Gsk-3*--dependent DMRs within 250 kb of the gene body in mouse ESCs. Of the 822 protein-coding putative imprinted genes identified in the RNA-Seq study, 424 (52%) had a *Gsk-3*--dependent DMR in the proximity. Similarly, 61% (166 of 274) genes for noncoding RNAs had a *Gsk-3*--dependent DMR nearby ([Figure 4](#F4){ref-type="fig"}). Taken together with our identification of 75% of previously known imprinted genes having *Gsk-3*--dependent DMRs, the correlation we see between *Gsk-3*--dependent DMRs in ESCs and putative brain imprinted genes strongly supports our hypothesis that Gsk-3 activity is critical for maintaining DNA methylation at a majority of loci subjected to imprinting. It is also worth noting the high concordance between the parent-of-origin bias in gene expression in the brain and the presence of DMRs at the same loci in ES cells. These data suggest that despite significant differences in cell types, the correlation between *Gsk-3*--dependent DMRs and imprinting is quite strong.

![DMR comparison. Venn diagram showing the overlap between known imprinted genes (green), Gsk-3--dependent DMRs (blue), and brain imprinted genes (orange).](2139fig4){#F4}

Comparison of Gsk-3-dependent DMRs with DMRs from uniparental ESCs
------------------------------------------------------------------

Obviously the most appropriate and informative comparison regarding imprinted genes would be to analyze DNA methylation differences in mouse ESCs. Fortunately, an experiment similar to ours was performed using methylated DNA immunoprecipitation-on-chip (meDIP-on-chip) in uniparental mouse ESCs ([@B17]). Because imprints arise from inheriting DNA methylation of an allele from only one parent, deriving ESCs from embryos containing only the maternal (parthenogenetic \[PG\]) or paternal (androgenetic \[AG\]) genome is quite useful for the study of genomic imprinting ([@B29]). Using meDIP-on-chip with PG and AG ESCs, [@B17] identified 458 DMRs---141 paternally methylated DMRs and 317 maternally methylated DMRs---many of which corresponded exactly to known imprinted genes. Therefore we compared the location of uniparental DMRs with our *Gsk-3*-dependent DMRs. We were quite surprised to find that 96 of 458 mapped precisely to DMRs identified in *Gsk-3* DKO ESCs (Supplemental Table S5). Furthermore, contrary to what was observed with our initial survey of known imprinted genes, the greatest degree of concordance between DMRs from the two data sets was seen with the maternal DMRs---83 of 317 DMRs (26.2%) overlap, whereas only 13 of 141 paternal DMRs (9.2%) overlap. Of the maternal overlapping DMRs, 17 are known to be at imprinted loci (Supplemental Table S5). Thus 66 DMRs that are shared between uniparental ESCs and *Gsk-3* DKO ESCs map to the exact same genomic region but have not been identified as imprinted. Examples of overlapping DMRs are shown for the *Gnas/Naspas* and *Nkx6-2* loci ([Figure 5](#F5){ref-type="fig"}). The comparison of the uniparental DMRs and *GSK-3*--dependent DMRs provides an additional level of independent validation of our MBD-Seq approach and significantly strengthens our conclusion that we identified biologically significant DMRs in *Gsk-3* DKO ESCs.

![Examples of overlapping DMRs from Gsk-3 DKO ESCs and uniparental ESCs. Gsk-3--dependent DMRs from the 2 M fraction are in red and from the 600 mM fraction are in blue, and the DMRs identified by [@B17], are in green. (A) *Gnas*/*Nespas* locus. (B) *Tcf21* locus. (C) *Nkx6-2* locus.](2139fig5){#F5}

Quantitative analysis of imprinted gene expression in Gsk-3 DKO ESCs
--------------------------------------------------------------------

Previous analysis of microarray gene expression data indicated that the expression of many imprinted genes was altered in *Gsk-3* DKO ESCs relative to WT ESCs ([@B38]; [@B4]). We set out to validate the observed changes in gene expression by performing quantitative PCR (qPCR). Relative levels of gene expression was determined for 91 murine imprinted genes, with expression levels normalized to *Gapdh*. A majority of the genes (68 of 91) were down-regulated in *Gsk-3* DKO ESCs, and of these, 37 were decreased in expression twofold or more compared with WT ESCs ([Table 3](#T3){ref-type="table"}). The greatest reductions in gene expression were for *Kcnq1*, *Cmah*, *Htr2a*, *Grb10*, *Slc22a2*, *Cdkn1c*, *Slc22a3*, *Wt1*, *Dlx5*, and *Drd1a* ([Figure 2C](#F2){ref-type="fig"} and [Table 3](#T3){ref-type="table"}). The remainder (23 of 91) were up-regulated in *Gsk-3* DKO ESCs, including seven that showed at least twofold increase in expression compared with WT ESCs ([Table 3](#T3){ref-type="table"}). The genes showing the largest increase in expression in *Gsk-3* DKO ESCs were *Peg10*, *Dhcr7*, *Klrb1f*, *Nespas*, *Xlr3c/Xlr3b/Xlr3a*, *Plagl1*, and *Xlr4b/Xlr4c/Xlr4a* ([Table 3](#T3){ref-type="table"}). These qPCR data confirm that the deletion of *Gsk-3* isoforms in mouse ESCs results in widespread changes in the expression of imprinted genes.

###### 

Summary of TaqMan qPCR data for imprinted genes in WT and *Gsk-3* DKO ESCs.

  --------------------
  ![](2139ufig1.jpg)
  --------------------

Values represent the fold change in *Gsk-3* DKO ESCs vs. WT ESCs. For all assays, *n* = 9 (3 biological replicates and 3 technical replicates) for each gene. Genes in red are increased twofold or more; genes in blue are decreased twofold or more.

Analysis of the *Hoxa* cluster in Gsk-3 DKO ESCs
------------------------------------------------

In addition to identifying DMRs associated with imprinted genes, we found a number of nonimprinted genes that exhibit Gsk-3--dependent reductions in DNA methylation, exemplified by the *Hoxa* gene cluster. Located on the distal arm of chromosome 6, the *Hoxa* cluster contains 11 homeobox genes within an ∼125-kb region. Strikingly, this region contained a relatively high number of *Gsk-3*-dependent DMRs---nine from the 2 M fraction and four from the 600 mM fraction ([Figure 6A](#F6){ref-type="fig"}). We were curious to learn whether the presence of these DMRs correlated with changes in gene expression. Therefore we examined the expression of the genes in the *Hoxa* cluster in WT and *Gsk-3* DKO ESCs by quantitative reverse transcription PCR (qRT-PCR) using TaqMan probes (three technical replicates on each of four biological samples; *n* = 12). Expression of all genes in the *Hoxa* cluster was decreased in *Gsk-3* DKO ESCs compared with WT ESCs, and, with the exception of *Hoxa1*, expression of all of the *Hoxa* genes was decreased by at least 60% ([Figure 6B](#F6){ref-type="fig"}). Taken together with the changes in gene expression and reduction in DNA methylation at imprinted loci, these data suggest that reductions in DNA methylation affect the transcription of genes in the *Hoxa* cluster and that this effect is influenced by Gsk-3 activity.

![Gsk-3-dependent DNA methylation and gene expression at the *Hoxa* locus. (A) Schematic representation of the *Hoxa* locus, along with the position of Gsk-3--dependent DMRs (2 M fraction in red, 600 mM fraction in blue). (B) qPCR data for all of the genes in the *Hoxa* cluster in WT and Gsk-3 DKO ESCs. For all results shown, RQ is relative quantification (all values were normalized to a GAPDH endogenous control); error bars represent SEM between biological replicates (*n* = 3) and technical replicates (*n* = 3; *n* = 9 total for each gene in each cell line).](2139fig6){#F6}

Correlation between gene expression and DNA methylation in Gsk-3 DKO ESCs
-------------------------------------------------------------------------

Because we had both microarray gene expression data and MBD-Seq data from Gsk-3 DKO ESCs, we sought to address how much correlation there is between reduced DNA methylation and changes in gene expression. Of the 2503 genes from the 2 M fraction that showed *Gsk-3*--dependent reduction in DNA methylation and the 1536 genes whose expression changed twofold or more in *Gsk-3* DKO ESCs versus WT ESCs, 299 were in common between the two studies ([Figure 7](#F7){ref-type="fig"}). Therefore there appears to be a correlation between DNA methylation and gene expression for ∼10--15% of genes affected in *Gsk-3* DKO ESCs. When we focus specifically on imprinted genes, *Gsk-3*xdependent DMRs are found near 64% (28 of 44) of imprinted genes whose expression increased or decreased at least twofold in the *Gsk-3* DKO ESCs (Supplemental Table S6).

![Integrating DNA methylation and gene expression. Venn diagram showing overlap between genes with Gsk-3--dependent DMRs (blue circle) and those genes whose expression is changed twofold or more in Gsk-3 DKO ESCs (orange circle).](2139fig7){#F7}

DISCUSSION
==========

The advent of new DNA sequencing technology ([@B30]), combined with enrichment of methylated DNA ([@B15]), has provided a genome-wide view of the epigenetic landscape in mammalian cells ([@B33]; [@B3]; [@B28]; [@B16]; [@B40]; [@B34]). Here we used that technology to examine the state of DNA methylation in mouse ESCs in which both *Gsk-3α* and *Gsk-3β* have been genetically deleted ([@B10]). Focusing specifically on regions of the mouse genome that were hypomethylated in *Gsk-3* DKO ESCs compared with WT ESCs, we unambiguously identified *Gsk-3*--dependent DMRs in the immediate proximity of three-fourths of known imprinted genes, extending our previous observation of reduced DNA methylation at the imprinted *H19/Igf2* and *Igf2r/Airn* loci in *Gsk-3* DKO ESCs ([@B38]). Because the DNA methylation at imprinted loci was already established by the time ESCs were isolated from mouse embryos, we believe that the reduction in DNA methylation is due not to a loss of imprinting but instead to an impairment in the maintenance of DNA methylation at these genomic regions. Furthermore, reexpression of human Gsk-3β in *Gsk-3* DKO ESCs fully restores DNA methylation deficits observed at the *H19/Igf2* locus (Supplemental Figure S3). In addition, treating WT ESCs with a small-molecule inhibitor of Gsk-3 activity results in a decrease in the activity of a reporter gene driven by the Dnmt3a2 promoter ([@B38]; Supplemental Figure S4). Taken together, these data demonstrate the importance of Gsk-3 activity in the maintenance of DNA methylation at imprinted loci, which is likely due to reduced *Dnmt3a2* expression ([@B38]).

Of interest, not all imprinted genes exhibited *Gsk-3*-dependent DNA methylation. Notably absent from the list of *Gsk-3*--dependent DMRs is the imprinted cluster on proximal chromosome 7 that includes *Atp10a*, *Ube3a*, *Ipw*, *Snurf*, and *Snrpn*, as well as the *Mirg* cluster of miRNAs on chromosome 12 ([@B26]; [@B11]). This suggests that maintenance of DNA methylation at these ICRs is regulated by a mechanism that is independent of Gsk-3 activity, adding an additional layer of complexity to the process of maintaining DNA methylation at imprinted loci.

In addition, the sex chromosomes were surprisingly devoid of *Gsk-3*--dependent DMRs. The X chromosome showed only seven 2 M fraction DMRs (all 1SD), and eleven 600 mM fraction DMRs (five 2SD DMRs), whereas there were no *Gsk-3*--dependent DMRs identified on the Y chromosome. Of the DMRs identified on the X chromosome, none were in close proximity to the gene cluster containing *Xlr3a*, *Xlr3b*, *Xlr3c*, *Xlr4a*, *Xlr4b*, and *Xlr4c*, genes whose expression was found to be substantially up-regulated in *Gsk-3* DKO ESCs compared with WT ESCs.

An initial genome-wide survey of DMRs drew our attention to the *Hoxa* locus because of the presence of 13 *Gsk-3*-dependent DMRs within a 125-kb genomic region. The identification of significant hypomethylation at the *Hoxa* gene cluster was particularly intriguing, given the functional importance of *Hoxa* genes in development and disease. Of particular relevance to this study, altered *Hoxa* DNA methylation and/or gene expression has been seen in pediatric acute lymphoblastic leukemia (ALL; [@B44]) and chronic lymphocytic leukemia (CLL; [@B35]). Furthermore, mutations in *DNMT3A* have been shown to cause acute myeloid leukemia (AML; [@B27]), suggesting a role for aberrant DNA methylation in AML. Of interest, Gsk-3 inhibitors have been found to be candidate therapeutics for the treatment of mixed lineage leukemia (MLL; [@B50]). Although all of these leukemias are molecularly distinct and have different etiologies, it is of interest to note the connection between Gsk-3 activity, DNA methylation, and *Hoxa* gene expression that is common to ALL, CLL, MLL, and AML. Recent mechanistic studies on MLL suggest that regulation of MEIS1 activity via Gsk-3--dependent control of CREB, TORC, and CBP could represent a common molecular link between these disparate cancers ([@B49]).

Although our data provide evidence that maintenance of DNA methylation at ICRs previously identified for several imprinted genes is *Gsk-3* dependent ([@B37]; [@B12]; [@B8]), the most compelling data come from the comparison of *Gsk-3*--dependent DMRs with DMRs identified in uniparental ESCs ([@B17]). Whereas both maternal and paternal contributions to the mammalian genome have been shown to be required for embryogenesis ([@B31]; [@B45]), PG and AG mice survive long enough for ESCs to be derived ([@B1]; [@B46]), providing a valuable resource for the study of uniparental epigenetics and the process of imprinting. Although the Arima group used a slightly different technique (meDIP-on-chip; [@B17]), the principle is similar to our MBD-Seq approach---enrichment of methylated DNA from different samples, followed by quantitative measurement of differences in DNA methylation between samples. We found a remarkable degree of overlap between the DMRs identified in these independent studies. In addition to a number of previously characterized imprinted genes, these studies suggest the possibility of additional imprinted genes. Using bisulfite sequencing, we validated the DMRs at one putatively imprinted gene, *Engrailed 1* (*En1*), a transcription factor that is known to be an important regulator of embryonic development ([@B41]). Further studies need to be performed to determine how many of the genes listed in Supplemental Table S5 are indeed imprinted.

Gsk-3 activity regulates multiple signal transduction pathways, such as Wnt and insulin signaling, and therefore is important for numerous biological processes ([@B21]). We now provide conclusive evidence that ESCs deficient in *Gsk-3α* and *Gsk-3β* have reductions in DNA methylation throughout the genome, with particular enrichment at imprinted loci. Of interest, there appears to be a difference between inhibition of Gsk-3 via insulin or Wnt signaling. We previously showed that constitutive activation of PI3K results in reduced DNA methylation at the H19/Igf2 locus ([@B38]), but this same effect is not seen in WT ESCs expressing a constitutively active form of β-catenin ([@B19]; Supplemental Figure S5). It will be interesting to see whether other signaling pathways that also modulate Gsk-3α/β activity via phosphorylation of N-terminal serine residues ([@B9]) have a similar effect on the DNA methylation of imprinted genes. When DNA methylation levels are integrated with microarray gene expression data, we observe that changes in gene expression are correlated with reduced DNA methylation. Our findings should serve as a platform for further study of *Gsk-3*--dependent biological functions. Of particular note, the mood stabilizer lithium directly inhibits Gsk-3 activity ([@B20]; [@B43]) and was shown to affect DNA methylation at the *H19/Igf2* ICR ([@B38]). Given that psychiatric illnesses such as bipolar disorder and schizophrenia have been suggested to have alterations in genomic DNA methylation patterns ([@B36]; [@B22]), our data raise the possibility that the effectiveness of lithium in the treatment of bipolar disorder could be through influencing DNA methylation. Further studies on cells from patients with bipolar disorder, especially neuronal cells, would help to address this possibility.

MATERIALS AND METHODS
=====================

Methylated DNA enrichment, SOLiD library construction, and SOLiD sequencing
---------------------------------------------------------------------------

Genomic DNA was isolated from wild-type and *Gsk-3* DKO ESCs and then sheared to 150-- to 200--base pair fragments using a Covaris sonicator. The MethylMiner kit (Invitrogen, Carlsbad, CA) was used to enrich for methylated DNA. DNA was eluted from beads using both low-salt (600 mM NaCl) and high-salt (2 M NaCl) conditions. Eluted DNA was blunt-end repaired, and adaptors were ligated onto the DNA fragments. Emulsion PCR and bead enrichment were then performed, followed by DNA sequencing on a SOLiD instrument (Applied Biosystems, Foster City, CA) with 10 ligation cycles, using five primer rounds ([@B32]). Fifty base pairs of each fragment were interrogated for sequence analysis.

Analysis of MethylMiner/SOLiD reads
-----------------------------------

Reads were mapped to reference genome mm9 using Bowtie ([@B23]). Clonal reads were removed to obtain nonredundant starts. MACS software was used to find peaks in the mapped reads ([@B53]). High-scoring peaks with significant differences in read pileups between WT and *Gsk-3* DKO samples were considered as putative DMRs. Hypomethylated DMRs in *Gsk-3* DKO ESCs were samples with fewer reads than WT ESCs for the same region. The mean and SD of significance scores (based on values) were determined, and the scoring peaks 1 or 2 SDs higher than the average score for the whole set were used to select for the most significant DMRs (Supplemental Table S2). To validate DMRs bioinformatically, the top scoring peaks were compared with true genome target regions (known imprinted loci) and false target regions. The numbers of hits in each class were calculated and compared with the numbers of hits expected by chance, given the size of the genome, the genomic footprint of each class, and the number of peaks.

Functional enrichment analysis
------------------------------

DMR functional enrichment studies were performed using ToppFun within the ToppGene Suite (toppgene.cchmc.org; [@B6]). ToppGene then performs functional enrichments, looking for sets of coregulated genes. Calculations are performed using false discovery rate for correction and a *p*-value cut-off of \<0.05.

Bisulfite PCR primers
---------------------

PCR primers for the amplification of the *Gsk-3*-dependent DMRs from bisulfite-converted genomic DNA were designed using the BiSearch primer design tool (bisearch.enzim.hu; [@B48]). The selected primers yielded a single amplified product for each desired region. Primer sequences are given in Supplemental Table S7.

Bisulfite sequencing
--------------------

High--molecular weight genomic DNA was fragmented by rapid freezing on dry ice and thawing at 42°C for five repetitions, and 500 ng of fragmented genomic DNA was bisulfite-converted with the Cells-to-CpG Bisulfite Conversion Kit (Life Technologies, Carlsbad, CA) per the manufacturer\'s instructions. Genomic regions were amplified from bisulfite-converted DNA with Platinum Taq (Life Technologies) using primers shown in Supplemental Table S7 under the following conditions: 94°C for 10 min, 5 cycles of 94°C for 45 s/54°C for 45 s/72°C for 1 min, followed by 30 cycles of 94°C for 45 s/59°C for 45 s/72°C for 1 min) followed by 72°C for 7 min. PCR products were TA cloned into pCR2.1 (Life Technologies). Plasmid clones were sequenced with M13 Reverse primer at Eton Bioscience (San Diego, CA) and the Molecular and Cellular Imaging Center at Ohio State University (Wooster, OH). Resulting sequences were analyzed using MacVector (Cary, NC) software. Identical clones and clones containing partially bisulfite-converted DNA were easily identified by analyzing patterns of non-CpG DNA methylation, which was still present in WT and *Gsk-3* DKO ESCs, and sub­sequently removed from analyses.

RNA isolation, cDNA synthesis, and quantitative PCR
---------------------------------------------------

TaqMan probes for 91 mRNAs ([@B51]) were subjected to a two-step RT-PCR protocol. For each assay,100 ng of total RNA was used, and reactions were run on an ABI HT7900 real-time PCR instrument. RNA was isolated from 5 × 10^5^ to 1 × 10^6^ WT and *Gsk-3* DKO ESCs using the MirVana Total RNA Isolation Kit (Applied Biosystems) according to the manufacturer\'s instructions. Then 100 ng of RNA was used for cDNA synthesis using the High Capacity cDNA reverse transcription kit (Applied Biosystems), following the manufacturer\'s protocol. Quantitative RT-PCR was performed on an ABI HT7900 real-time PCR instrument using TaqMan master mix and TaqMan assays (Applied Biosystems). TaqMan probe IDs are listed in Supplemental Table S8. Three biological replicates and three technical replicates were used for WT and *Gsk-3* DKO ESCs. All threshold cycle (*Ct*) values were normalized to a mouse *Gapdh* endogenous control (Applied Biosystems), and relative quantification was calculated from the median *Ct* value ([@B39]).

Microarray and statistical analysis of microarray data
------------------------------------------------------

RNA was measured in an ND-1000 UV-Vis spectrophotometer (Thermo Fisher Scientific, Waltham, MA), and a 2100 Bioanalyzer Lab-On-A-Chip 6000 Series II chip (Agilent, Santa Clara, CA) was used to determine the integrity of the samples. RNA from each cell line was hybridized onto a SurePrint G3 Mouse GE 8 × 60K Microarray, AMADID 028005 (Agilent). Hybridization was performed overnight at 45ºC. We performed arrays for each cell line using RNA that was isolated in biological triplicate (*n* = 3). For Gsk-3 DKO ESCs, we used *n* = 4 biological replicates. SurePrint arrays were scanned with a G2505C Microarray Scanner (Agilent). Additional details can be found in [@B4].

Luciferase assay
----------------

Wild-type ESCs stably transfected with Dnmt3a2-luciferase ([@B38]) were treated with 10 μM SB-415,286 for 3 d. After each day, cells were collected in luciferase lysis buffer and stored at −20°C. At the end of the time course, firefly luciferase assays were performed according to the manufacturer\'s protocol (Biotium, Hayward, CA) and measured in a Perkin Elmer-Cetus EnSpire Multimode Plate Reader. Three replicates were performed for each treatment group.
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DMR

:   differentially methylated region

Dnmt3a2

:   DNA methyltransferase 3a, isoform 2

Gsk-3

:   glycogen synthase kinase-3

*Gsk-3* DKO

:   *Gsk-3α* and *Gsk-3β* double knockout

Igf2

:   insulin-like growth factor 2

ICR

:   imprinted control region.
